AX-2025-019079 · GHRP-6 · GSP lot GSP-2508-F3139

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 25 min gradient, 214 nm	99.57	% area	≥ 99.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.43	% area	≤ 1.0	PASS
Largest single impurity	RP-HPLC — bis-oxidised Trp (+32 Da)	0.17	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	872.4446	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, unit resolution (single quadrupole)	872.4356	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-10.3	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	6.31	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	5.24	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.26	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.82	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 25 min gradient	7.16	min	7.15 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.97	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	60,842	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Trp]-epimer	0.84	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 25 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 60,842, and skew follows the reported asymmetry factor of 0.97. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.17 % impurity against a 99.57 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	GHRP-6 — main peak	7.16	4,839,411	99.57	—
2	bis-oxidised Trp (+32 Da)	6.68	8,263	0.17	+31.990
3	oxidised Trp (+16 Da)	6.88	8,263	0.17	+15.995
4	[D-Trp]-epimer	7.06	2,430	0.05	0.000
5	des-Lys (−128 Da)	6.98	1,944	0.04	-128.095
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 872.4446 Da, computed from C46H56N12O6. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, unit-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 872.4356 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	437.2296	437.2251	-0.0045	58.1
1+	873.4519	873.4429	-0.0090	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.73	99.57	divergence +0.16 pp vs batch median
Total impurities (% area)	not stated	0.43
Largest single impurity (% area)	not stated	0.17
Water (%)	5.2	6.31
Counter-ion (%)	not stated	5.24
Peptide content (%w/w)	90.0	not determined
Endotoxin (EU/mg)	0.29	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Laboratory-retained
Evidentiary weight: Provenance documented, selection uncontrolled.
Chain of custody: Laboratory retained sample (−20 °C, 8 d since original receipt) → re-assay.
Assay date: 17 Aug 2025
Submitted to the index: 31 Aug 2025
Laboratory: Medutest, Ljubljana, Slovenia
Method basis: 25 min gradient · unit-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

That the compound is not a near-isobaric alternative. Identity was confirmed at unit mass resolution, which cannot exclude species differing by 1 or 2 Da. The specific alternatives not excluded are named in the identity block above.
How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 2

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

des_gly31 Aug 2025

At 99.57 % the deletion-sequence family is at or below the reporting threshold. On a sequence with a hindered coupling that is a statement about coupling efficiency, and a good one.

gradient_2531 Aug 2025

Purity at 99.57 % and water at 6.31 %: the two numbers are independent and both are needed. Excellent chromatography on a wet cake still yields less peptide per vial than the label implies.

Section 7

Related records

Same batch — lot GSP-2508-F3139 n=11

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2025-019076	GSP-2508-F3139	Janoshik	2025-Q3	99.47	7.07	—	Buyer-sourced	PASS
AX-2025-019077	GSP-2508-F3139	VendorInvestigate	2025-Q3	99.93	7.12	94.6	Buyer-sourced	PASS
AX-2025-019078	GSP-2508-F3139	Janoshik	2025-Q3	99.49	7.01	90.4	Buyer-sourced	PASS
AX-2025-019080	GSP-2508-F3139	PeptideMeter	2025-Q3	99.75	6.88	—	Buyer-sourced	PASS
AX-2025-019081	GSP-2508-F3139	VendorInvestigate	2025-Q3	99.28	7.01	96.9	Buyer-sourced	PASS
AX-2025-019082	GSP-2508-F3139	Nordanalyt	2025-Q3	99.52	6.80	—	Buyer-sourced	PASS
AX-2025-019083	GSP-2508-F3139	VendorInvestigate	2025-Q3	99.68	6.62	96.5	Buyer-sourced	PASS
AX-2025-019084	GSP-2508-F3139	PeptideMeter	2025-Q3	99.70	6.79	—	Buyer-sourced	PASS
AX-2025-019085	GSP-2508-F3139	PeptideMeter	2025-Q3	99.26	6.43	105.5	Buyer-sourced	PASS
AX-2025-019086	GSP-2508-F3139	PeptideMeter	2025-Q3	99.61	6.54	105.8	Buyer-sourced	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent GHRP-6 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042012	AMB	AMB-2603-S5667	Janoshik	2026-Q3	99.37	5.90	88.8	Laboratory-retained	1	MARGINAL
AX-2026-042528	HJ	HJ-2603-R5329	VendorInvestigate	2026-Q3	98.69	1.87	95.8	Buyer-sourced	0	FAIL
AX-2026-042015	AMB	AMB-2603-S5667	Janoshik	2026-Q3	99.54	6.44	97.1	Buyer-sourced	0	PASS
AX-2026-042526	HJ	HJ-2603-R5329	Medutest	2026-Q3	99.37	3.06	—	Laboratory-retained	0	PASS
AX-2026-042527	HJ	HJ-2603-R5329	VendorInvestigate	2026-Q3	99.21	2.77	93.2	Buyer-sourced	0	PASS
AX-2026-042525	HJ	HJ-2603-R5329	Janoshik	2026-Q3	99.52	3.24	92.0	Buyer-sourced	0	PASS
AX-2026-042013	AMB	AMB-2603-S5667	Kestrel	2026-Q3	99.93	5.75	—	Buyer-sourced	0	PASS
AX-2026-042017	AMB	AMB-2603-S5667	Medutest	2026-Q3	99.76	6.42	97.4	Buyer-sourced	0	PASS

Other recent GSP records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041831	Survodutide	GSP-2603-E3156	Kestrel	2026-Q3	99.91	5.50	93.2	Buyer-sourced	0	PASS
AX-2026-041836	Survodutide	GSP-2603-E3156	Janoshik	2026-Q3	98.65	5.34	90.3	Buyer-sourced	0	PASS
AX-2026-041837	Survodutide	GSP-2603-E3156	Janoshik	2026-Q3	98.33	5.37	—	Buyer-sourced	0	PASS
AX-2026-041833	Survodutide	GSP-2603-E3156	Janoshik	2026-Q3	98.08	4.91	99.3	Buyer-sourced	0	PASS
AX-2026-041832	Survodutide	GSP-2603-E3156	VendorInvestigate	2026-Q3	98.01	5.14	99.5	Buyer-sourced	0	PASS
AX-2026-041835	Survodutide	GSP-2603-E3156	Nordanalyt	2026-Q3	98.34	5.74	89.0	Buyer-sourced	1	MARGINAL
AX-2026-041834	Survodutide	GSP-2603-E3156	VendorInvestigate	2026-Q3	97.92	5.95	—	Buyer-sourced	0	PASS
AX-2026-041838	Survodutide	GSP-2603-E3156	PeptideMeter	2026-Q3	98.30	5.01	102.4	Buyer-sourced	0	PASS